The use of real world data in cancer drug development
Journal article, Peer reviewed
Accepted version
Permanent lenke
http://hdl.handle.net/11250/2561458Utgivelsesdato
2018Metadata
Vis full innførselSamlinger
Originalversjon
European Journal of Cancer. 2018, 101 69-76. https://doi.org/10.1016/j.ejca.2018.06.036Sammendrag
Excitement about the dramatic increase in potential successful anticancer medicines in recent years is hampered by the high costs involved as well as the length of time traditional pathways take for regulatory approval. The translation of experimental clinical data into real-world evidence is also problematic. While the randomised controlled trial remains the gold standard for assessing efficacy and safety, there is increasing interest in the use of observational data to enable more rapid, informed and widespread availability and access to important anticancer medicines. Taking real-world evidence into account in regulatory and health technology assessment in a thoughtful and balanced fashion will enrich and justify sound decision-making.